A novel genetic assay for risk assessment of cognitive decline in Alzheimer’s Disease

Project description

Earlier diagnosis of Alzheimer's by a new genetic assay

Early diagnosis of Alzheimer’s disease relies on testing that is not easily applicable to the broader population. However, early diagnosis for both families and health providers are crucial as its incidence is expected to triple by 2050 from the current estimate of 45 million. The variaTECT method uses 130K single nucleotide polymorphism (SNP) testing and software to analyse DNA extracts from blood or saliva samples. It is 85 % accurate with significant cost savings for patients and revenue for genetic laboratories. The project will upgrade variaTECT’s design to determine dementia types and increase production capacity, aiming for clinical trials for an in-vitro diagnostic device.

Fields of science

• natural sciences › computer and information sciences › software
• medical and health sciences › basic medicine › neurology › dementia › alzheimer
• humanities › arts › architectural design
• natural sciences › biological sciences › genetics › nucleotides
• engineering and technology › medical engineering › diagnostic imaging › magnetic resonance imaging

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

CYTOX LIMITED

Net EU contribution

€ 50 000,00

Address

53 Fountain Street
M2 2AN Manchester
United Kingdom

Region

North West (England) › Greater Manchester › Manchester

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Non-EU contribution

€ 21 429,00